Cystic Fibrosis Pipeline Landscape 2020: Therapeutics Development & Assessment, Companies Involved, Drug Profiles

DUBLIN, May 13, 2020 /PRNewswire/ -- The "Cystic Fibrosis - Pipeline Review, H1 2020" drug pipelines has been added to's offering.

This pipeline guide provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 4, 34, 20, 1, 67, 32 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


    --  The pipeline guide provides a snapshot of the global therapeutic
        landscape of Cystic Fibrosis (Respiratory).
    --  The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis
        (Respiratory) by companies and universities/research institutes based on
        information derived from company and industry-specific sources.
    --  The pipeline guide covers pipeline products based on several stages of
        development ranging from pre-registration till discovery and undisclosed
    --  The pipeline guide features descriptive drug profiles for the pipeline
        products which comprise, product description, descriptive licensing and
        collaboration details, R&D brief, MoA & other developmental activities.
    --  The pipeline guide reviews key companies involved in Cystic Fibrosis
        (Respiratory) therapeutics and enlists all their major and minor
    --  The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics
        based on mechanism of action (MoA), drug target, route of administration
        (RoA) and molecule type.
    --  The pipeline guide encapsulates all the dormant and discontinued
        pipeline projects.
    --  The pipeline guide reviews latest news related to pipeline therapeutics
        for Cystic Fibrosis (Respiratory).

Reasons to Buy

    --  Procure strategically important competitor information, analysis, and
        insights to formulate effective R&D strategies.
    --  Recognize emerging players with potentially strong product portfolio and
        create effective counter-strategies to gain competitive advantage.
    --  Find and recognize significant and varied types of therapeutics under
        development for Cystic Fibrosis (Respiratory).
    --  Classify potential new clients or partners in the target demographic.
    --  Develop tactical initiatives by understanding the focus areas of leading
    --  Plan mergers and acquisitions meritoriously by identifying key players
        and it's most promising pipeline therapeutics.
    --  Formulate corrective measures for pipeline projects by understanding
        Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication
    --  Develop and design in-licensing and out-licensing strategies by
        identifying prospective partners with the most attractive projects to
        enhance and expand business potential and scope.
    --  Adjust the therapeutic portfolio by recognizing discontinued projects
        and understand from the know-how what drove them from pipeline.

Key Topics Covered

    1. Introduction
    2. Overview
    3. Therapeutics Development
    4. Therapeutics Assessment
    5. Companies Involved in Therapeutics Development
    6. Drug Profiles
    7. Dormant Projects
    8. Discontinued Products
    9. Product Development Milestones
    10. Appendix

Companies Mentioned

    --  4D Molecular Therapeutics Inc
    --  AbbVie Inc
    --  Abeona Therapeutics Inc
    --  Agile Sciences Inc
    --  AGILeBiotics BV
    --  Airway Therapeutics LLC
    --  Alaxia SAS
    --  AlgiPharma AS
    --  Altavant Sciences Inc
    --  Amgen Inc
    --  Antabio SAS
    --  Arch Biopartners Inc
    --  Arcturus Therapeutics Ltd
    --  Armata Pharmaceuticals Inc
    --  Arrevus Inc
    --  Arrowhead Pharmaceuticals Inc
    --  AstraZeneca Plc
    --  Atlantic Healthcare Plc
    --  Avidin Ltd
    --  BioAegis Therapeutics Inc
    --  Biofilm Pharma
    --  Biolytx Pharmaceuticals Corp
    --  Boehringer Ingelheim International GmbH
    --  Boston Pharmaceuticals Inc
    --  Breathe Easy Therapeutics Ltd
    --  BridgeBio Pharma Inc
    --  Calista Therapeutics Inc
    --  Calithera Biosciences Inc
    --  Catabasis Pharmaceuticals Inc
    --  Celtaxsys Inc
    --  Chiesi Farmaceutici SpA
    --  Chrysalis Pharma SAS
    --  Cilian AG
    --  Copernicus Therapeutics Inc
    --  Corbus Pharmaceuticals Inc
    --  CRISPR Therapeutics AG
    --  CrowdOut Therapeutics
    --  CSA Biotechnologies LLC
    --  Cyclacel Pharmaceuticals Inc
    --  Cyclenium Pharma Inc
    --  Daiichi Sankyo Co Ltd
    --  Destiny Pharma Plc
    --  DiscoveryBiomed Inc
    --  Druggability Technologies Holdings Ltd
    --  Editas Medicine Inc
    --  Eloxx Pharmaceuticals Inc
    --  EmphyCorp Inc
    --  EnBiotix Inc
    --  Enterprise Therapeutics Ltd
    --  Entrinsic Health Solutions, Inc.
    --  Enzyvant Sciences Ltd
    --  Errant Gene Therapeutics LLC
    --  Evaxion Biotech ApS
    --  Evotec SE
    --  Exotect LLC
    --  Galapagos NV
    --  Galenus Therapeutics Inc
    --  Generation Bio Corp
    --  Genzyme Corp
    --  Grupo Praxis Pharmaceutical SA
    --  Helperby Therapeutics Group Ltd
    --  Horizon Therapeutics PLC
    --  Icagen Inc
    --  Idorsia Pharmaceutical Ltd
    --  Immun System IMS AB
    --  Insmed Inc
    --  Invion Ltd
    --  Ionis Pharmaceuticals Inc
    --  Kamada Ltd
    --  Kither Biotech Srl
    --  Kyorin Pharmaceutical Co Ltd
    --  Lakewood-Amedex Inc
    --  Lamellar Biomedical Ltd
    --  Laurent Pharmaceuticals Inc
    --  MannKind Corp
    --  Mariposa Health Ltd
    --  Microbion Corp
    --  Mucokinetica Ltd
    --  Nanogenics Ltd
    --  Neupharma Srl
    --  New Amsterdam Sciences Inc
    --  Novabiotics Ltd
    --  Novartis AG
    --  Novoteris LLC
    --  Omnispirant Ltd
    --  Orphomed Inc
    --  OrPro Therapeutics Inc
    --  Oryn Therapeutics
    --  Paranta Biosciences Ltd
    --  Parion Sciences Inc
    --  Pharmaero ApS
    --  Pharmaxis Ltd
    --  PhaseBio Pharmaceuticals Inc
    --  Polyphor AG
    --  Progenra Inc
    --  ProQR Therapeutics NV
    --  Protalix BioTherapeutics Inc
    --  Proteostasis Therapeutics Inc
    --  Pulmatrix Inc
    --  Rare Partners Srl
    --  Recode Therapeutics Inc
    --  Renovion Inc
    --  Riptide Bioscience Inc
    --  Santhera Pharmaceuticals Holding AG
    --  SciBac Inc
    --  Sequoia Sciences Inc
    --  Silurian Pharmaceuticals Inc
    --  SolAeroMed Inc
    --  Specific Biologics Inc
    --  Spirovant Sciences Inc
    --  Spyryx Biosciences Inc
    --  Synedgen Inc
    --  Synovo GmbH
    --  Synspira LLC
    --  Takeda Pharmaceutical Co Ltd
    --  TGV-Inhalonix Inc
    --  Therapeutic Systems Research Laboratories Inc
    --  Translate Bio Inc
    --  Trucode Gene Repair Inc
    --  Vast Therapeutics Inc
    --  Vectura Group Plc
    --  Verona Pharma Plc
    --  Vertex Pharmaceuticals Inc
    --  Vironika LLC
    --  Zambon Co SpA
    --  Zata Pharmaceuticals Inc
    --  Zikani Therapeutics Inc

For more information about this drug pipelines report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets